Skip to main content Skip to navigation

Trial overview

Trial Title Sugammadex for preventIoN of pOst-operative pulmoNary complIcAtions - SINFONIA
Primary objective To determine whether sugammadex is superior to neostigmine after elective or emergency major abdominal or non-cardiac thoracic surgery in terms of days alive and out of hospital at 30 days (DAH30)
Trial Design Randomised clinical trial with embedded observational study
Trial Participants Patients aged >50 year old undergoing elective or emergency major abdominal or non-cardiac thoracic surgery planned to receive neuromuscular blockade with rocuronium or vecuronium with reversal at the end of surgery
Exclusion Criteria

1. Known allergy to sugammadex, neostigmine or glycopyrrolate

2. Lack of written informed consent for trial participation

3. Planned invasive mechanical ventilation before or after surgery

4. Previous participation in SINFONIA trial

5. Clinician refusal

Sample Size 2500
Treatment Duration Single bolus dose, repeated once if deemed necessary by the treating clinician
Follow-up Duration 180 days
Outcome Measures

1. Days alive out of hospital at 30 days (DAH30)

2. Post-operative Pulmonary Complications (PPCs) within seven days after surgery

3. Mortality at 30 days and 180 days after surgery

4. Health-related quality of life at 7, 30 and 180 days (EQ-5D-5L)

5. Allergic reaction within 24 hours after administration of IMP


Please find attached below v3.0 of the Sinfonia Trial protocol

Protocol v3.0Link opens in a new window

Contact Us:

Trial Manager: Kirsten Harris

Trial Coordinator: Hannah McNeil

Data Entry Clerk: David Lomax

Tel: +44 (0)24 7615 0963


Sinfonia Trial Team,
Warwick Clinical Trials Unit,
Warwick Medical School,
University of Warwick,
Gibbet Hill Campus,